GLP1R and diabetic retinopathy: Intriguingly, the repurposing of GLP1 receptor agonists (e.g., semaglutide) for diabetic retinopathy (DR) remains controversial, with some studies suggesting potential benefits for metabolic and ocular health—such as reduced systemic inflammation and macrovascular risk—while others report the early worsening of DR after initiation.